Congestive Heart Failure
Conditions
Keywords
albuterol
Brief summary
This is a randomized trial of the use of Albuterol in the setting of acute decompensated Congestive Heart Failure with radiographic evidence of Cardiogenic Pulmonary Edema.
Detailed description
The objective is to carry out a randomized blinded placebo-controlled trial of inhaled Albuterol as an early therapy for patients with decompensated Congestive Heart Failure. Compared to placebo, inhaled Albuterol will improve oxygenation and decrease the need for non-invasive ventilation in patients with Cardiogenic Pulmonary Edema.
Interventions
DRUGAlbuterol
2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
DRUGNormal Saline
2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
Sponsors
University of California, San Francisco
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* age 18-65 with shortness of breath and history of CHF * pulmonary edema on chest xr
Exclusion criteria
* pregnancy * clinical or ekg changes to suggest acute coronary syndrome * history of copd or asthma * history of albuterol on medication list
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Borg Dyspnea Score | 8 hours. | Patients are evaluated for approximatly 8 hours with the Borg Dyspnea Score. Starting at the time of arrival, then one hour later and consequently every two hours until reaching 8 hours in total. The Borg score is used to quantify the degree of shortness of breath a person is experiencing which is a measured on a 10 point visual-analog scale. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Admission | An average of 48 hours | If the patient is hospitalized we will continue to record information about their hospital stay and the patient will not receive more study interventions. |
Countries
United States
Outcome results
None listed